Mechanism of Action
Emerging research explores how EBC-46 may influence mitochondrial membrane integrity, potentially contributing to tumour cell apoptosis through intrinsic pathway activation.
Stelfonta
How EBC-46 became Stelfonta® — the first FDA and EMA approved intratumoral cancer treatment — through rigorous canine clinical trials, and what this milestone means for the ongoing Phase I/II human cancer trials.
Clinical Trials
A detailed review of EBC-46 (tigilanol tiglate) human clinical trial data through 2025–2026, including Phase I/II results for soft tissue sarcoma, melanoma, and other solid tumours, response rates, and the path to FDA approval.
EBC-46
A deep-dive into how tigilanol tiglate (EBC-46) destroys tumours through three distinct pathways: PKC activation, rapid vascular disruption, and immune-mediated clearance — with full citations to the primary research.
EBC-46
The definitive reference on EBC-46 (tigilanol tiglate): its chemistry, mechanism of action, veterinary approval as Stelfonta®, ongoing human Phase I/II trials, Blushwood berry source, and what current science says for patients and supplement users.